April 19, 2024
Open-Angle Glaucoma Articles
March 1, 2024
Travoprost Implant Noninferior to Twice-daily Timolol 0.5% Drops
By Conni Koury, contributing writer
December 18, 2023
Glaukos iDose TR Gets FDA Approval
By Conni Koury, contributing writer
December 1, 2023
Trials in Focus: The COAST Trial of Selective Laser Trabeculoplasty
By Tony Realini, MD, MPH
December 1, 2023
Cilioscleral Device Significantly and Safely Reduced IOP at 1 Year
By Conni Koury, contributing writer
December 1, 2023
Fixed High-energy SLT Superior to Standard Titrated Protocol for IOP Lowering
By Conni Koury, contributing writer
December 1, 2023
Netarsudil Plus Latanoprost Noninferior to Bimatoprost-timolol Combo
By Conni Koury, contributing writer
December 1, 2023
Miniject Safe and Effective at 3 Years
By Conni Koury, contributing writer
December 1, 2023
ViaLase Completes Enrollment for Pivotal Trial of Laser for POAG
By Jennifer Ford, senior managing editor
September 1, 2023
Prospects for Optic Nerve Regeneration and Vision Restoration in Patients With Glaucoma
By Thomas V. Johnson, MD, PhD
September 1, 2023
First-in-Class, Dual-MOA Small-molecule Glaucoma Treatment Met Primary Endpoints in Phase 2a Trial
By Conni Koury, contributing writer
September 1, 2023
Product Spotlight: Minimally Invasive, Implant-free MIGS
By Karen Appold, contributing writer
June 1, 2023
Nova Eye Medical Announces 510(k) Clearance of iTrack Advance
By Rochelle Nataloni, contributing writer
June 1, 2023
ViaLase Announces Positive Data on Femtosecond Laser Trabeculotomy
By Rochelle Nataloni, contributing writer
June 1, 2023
STAR-VI Trial Begins for Miniject With Cataract Surgery
By Rochelle Nataloni, contributing writer
June 1, 2023
iStent Inject With Cataract Surgery as Safe as Cataract Surgery Alone
By Rochelle Nataloni, contributing writer
June 1, 2023
Gel Stent Noninferior to Trabeculectomy in Open-angle Glaucoma
By Rochelle Nataloni, contributing writer
June 1, 2023
Iyuzeh Shows Similar IOP Lowering to Xalatan in Phase 3 Study
By Rochelle Nataloni, contributing writer
March 1, 2023
The Future of Fields
By James T. Murphy, MD
March 1, 2023
Episcleral Venous Pressure and Flow
By Abdelrahman M. Elhusseiny, MD, Osamah J. Saeedi, MD
March 1, 2023
The Importance of Genetic Biomarkers for Glaucoma
By Brandon Minh Le, Louis R. Pasquale, MD
March 1, 2023
Changes in Glaucoma Management Following Diurnal Home Tonometry
By Anna Do, MD, Joseph F. Panarelli, MD
March 1, 2023
Treatment of Severe Ocular Surface Disease in the Glaucoma Patient
By Laura Voicu, MD, Sarwat Salim, MD, FACS
March 1, 2023
From the Editor: A Love Letter to Latanoprost
By Nathan M. Radcliffe, MD
March 1, 2023
Glaucoma Myth Busters: Myths About Prostaglandin Analogues and Inflammation
By Khin P. Kilgore, MD, Jason D. Jensen, MD, Sean J. McCafferty, MD
March 1, 2023
Visiox Submits NDA for First Once-daily Brimonidine
By Conni Koury, contributing writer
March 1, 2023
Six-year Results from LiGHT Trial Confirm SLT's Safety, Efficacy
By Conni Koury, contributing writer
December 16, 2022
Thea Pharma Receives FDA Approval for Iyuzeh Preservative-free Latanoprost
By Jennifer Ford, senior managing editor
December 1, 2022
FDA Approves Omlonti for IOP Reduction in POAG Patients
By Conni Koury, contributing writer
December 1, 2022
Early Onset of Diabetes, Hypertension Can Predict Early Glaucoma
By Conni Koury, contributing writer
December 1, 2022
LiGHT 6-year Results Show SLT Safe for OAG, Superior to Drops
By Conni Koury, contributing writer
December 1, 2022
Omni 3-year Standalone Data Show IOP Efficacy, Reduced Need for Meds in OAG Patients
By Conni Koury, contributing writer
September 1, 2022
From the Editor: Five Years of Glaucoma Physician
By Nathan M. Radcliffe, MD
September 1, 2022
Genetic Evidence Finds Habitual Coffee Consumption Increases POAG Risk
By Conni Koury, contributing writer
September 1, 2022
Phase 2 Data Favorable for QLS-101 Safety, Efficacy
By Conni Koury, contributing writer
September 1, 2022
Implant-free MIGS Reduced IOP, Fluctuations, and Medications
By Conni Koury, contributing writer
June 1, 2022
Modest Link Between IOP Rise and Alcohol Use
By Conni Koury, contributing writer
June 1, 2022
Miniject STAR-V Trial Initiated, Progress Reported
By Conni Koury, contributing writer
March 1, 2022
Study: Durysta Bimatoprost Implant Effective for OAG, Ocular Hypertension
By Conni Koury, contributing writer
March 1, 2022
The INFINITE Trial: Three Stents Resulted in Meaningful IOP Reduction in Population With Advanced Disease
By Conni Koury, contributing writer
March 1, 2022
Swept-source OCT in Primary Angle-closure Disease an Effective Diagnostic
March 1, 2022
Coding: New MIGS CPT Codes
By Kevin J. Corcoran, COE, CPC, CPMA, FNAO
December 1, 2020
Ocular Blood and Aqueous Flow in Relation to Development of Open-angle Glaucoma
By Sahar Bedrood, MD, PhD, Brian Nguyen, BS
December 1, 2020
Nicox Begins Second Phase 3 Trial of NCX 470
By Jerry Helzner, contributing editor
December 1, 2020
Sight Sciences Says OMNI System Effective in Open-angle Glaucoma
By Jerry Helzner, contributing editor
September 1, 2020
Tips and Tricks for Durysta Injection
By E. Randy Craven, MD
June 1, 2020
Nicox Clinical Trial Update
By Jerry Helzner, contributing editor
June 1, 2020
Trabeculotomy Combination Procedure Effective in Cataract-Glaucoma Surgery
By Jerry Helzner, contributing editor
June 1, 2020
New, Detailed Phase 3 Data on Durysta Implant Presented at ASCRS
By Jerry Helzner, contributing editor
June 1, 2020
MIGS Decision-Making Discussed at ASCRS
By Jennifer Ford, senior managing editor
March 6, 2020
FDA Approves Breakthrough Sustained-Release Glaucoma Implant
By Jerry Helzner, contributing editor
March 4, 2020
Second Phase 3 Trial Validates Efficacy of Bimatoprost SR
By Jerry Helzner, contributing editor
March 1, 2020
Lens Extraction With Endocycloplasty to Treat Plateau Iris
By Robert Feldman, MD
March 1, 2020
The Glaucoma Therapy Pipeline
By John R. Samples, MD
March 1, 2020
Intraocular Pressure and Medication Reduction Across Glaucoma Severities With the Kahook Dual Blade
By Syril K. Dorairaj, MD, and, Jella An, MD
March 1, 2020
From the Editor: Inertial vs Interventional Glaucoma Care
By Nathan M. Radcliffe, MD
March 1, 2020
Aerpio Has Good Early Data in Tie2 Regulation
By Jerry Helzner, contributing editor